Timothy Peterson
Practice Areas
Education
  • J.D., Georgetown University Law Center, 1998
  • M.B.A., The Ohio State University, 1993
  • A.B., English Literature, Miami University, 1991
Admissions
  • District of Columbia
  • New York
  • U.S. District Court, Southern District of New York

Timothy Peterson

tpeterson@mmlawus.com
C: (571) 228-4592
1001 G Street, N.W.
Seventh Floor
Washington, DC 20001
T: (202) 661-7027
F: (202) 661-7059

Seminars and Presentations

  • New FIFA Indictments
    01/05/2016 (09:19 AM - 09:19 AM) | (01/05/2016)

    “New FIFA indictments,” Interview, Compliance & Ethics Report #223 (January 5, 2016).

  • Exploring the Differing Roles of Corporate and Government Attorneys in Regulatory Investigations
    11/05/2015 | (11/05/2015)

    "Exploring the Differing Roles of Corporate and Government Attorneys in Regulatory Investigations,” Panelist, Virginia Bar Association Annual Administrative Law Conference (November 5, 2015).

  • FIFA Bribery Scandal and SEC Investigations
    07/24/2015 | (07/24/2015)

    FIFA Bribery Scandal and SEC Investigations,” Interview, Compliance and Ethics Report #179.

  • FIFA Indictments
    05/28/2015 | (05/28/2015)

    FIFA Indictments,” Interview, TRT World News Istanbul.

  • "Using Government Guidelines to Advise and Protect Your Clients," Forensic Accounting and Litigation Services Conference
    05/19/2015 | (05/19/2015)

    Mr. Peterson is a speaker for “Using Government Guidelines to Advise and Protect Your Clients,” at 2015 Forensic Accounting and Litigations Services Conference.  In today’s environment, companies are routinely in the government’s crosshairs. As the U.S. Attorney in Manhattan has said, every time the U.S. Attorney’s Office investigates an individual at a company involved with a crime, the prosecutors consider whether the company should also be charged.

  • What USDOJ and SEC Now Expect from Pharmaceutical, Biotechnology, Medical Device Companies, and CRO's
    04/27/2015 | (04/27/2015)

    Mr. Peterson is a panelist for “What USDOJ and SEC Now Expect from Pharmaceutical, Biotechnology, Medical Device Companies, and CROs,” at the American Conference Institute, FCPA and Anti-Corruption for the Life Sciences Industry.  U.S. and international enforcement authorities have continued their vigorous pursuit of life sciences companies for FCPA and anti-corruption violations, resulting in recent high profile investigations across the globe and heightened government compliance expectations.